stockrowAchieve Life Sciences, Inc.
ACHV Healthcare Biotechnology
- EPS
- −116.2%
- Free cash flow
- −19.0%
- Total debt
- +63.9%
Quarter to June 2026, against a year earlier
Follow ACHV
Alert me
Achieve Life Sciences, Inc. (ACHV) EV/Sales
As of 6 November 2026, Achieve Life Sciences, Inc. (ACHV) trades at a EV/Sales of 29.0×. Over the past ten years it has ranged from −3.1× (February 2016) to 39.6× (August 2026); the current reading is higher than 98% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2016 | 0.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2016 | −0.6× | — |
| Mar 2016 | −1.7× | — |
| Sep 2015 | −0.1× | — |
| Jun 2015 | −0.3× | — |
| 1 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SGMT Sagimet Biosciences Inc. compare | n/m |
| ATTO Attovia Therapeutics, Inc. compare | n/m |
| AURA Aura Biosciences, Inc. compare | n/m |
| WVE WAVE Life Sciences Ltd. compare | 3.6× |
| ZVRA Zevra Therapeutics, Inc. compare | 4.0× |
| DNA Ginkgo Bioworks Holdings, Inc. compare | 4.0× |
| FDMT 4D Molecular Therapeutics, Inc. compare | 5.7× |
| ACHV Achieve Life Sciences, Inc. | 29.0× |
| SLDB Solid Biosciences Inc. compare | 57.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)